REDMOND, Wash.--(BUSINESS WIRE)--Spiration, Inc., a developer of novel medical technology designed to benefit patients with acute and chronic conditions of the lung, today announced that the first patients have been enrolled in the company’s IBV Valve Trial in the United States. The purpose of the trial is to generate safety and effectiveness data for submission to the U.S. Food and Drug Administration (FDA) for approval to market the company’s IBV Valve System in the United States for the treatment of patients with severe emphysema.
